MarketCap
Facebook
X
TelegramAnnual report 2024
added 03-07-2026
XTL Biopharmaceuticals Ltd. Market Cap 2011-2026 | XTLB
As of March 16, 2026 XTL Biopharmaceuticals Ltd. has a market cap of $ 442 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap XTL Biopharmaceuticals Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 1.27 B | 16.6 M | 6.89 M | 11.8 M | 8.42 M | 8.22 M | 17.4 M | 23.1 M | 41.3 M | 65.3 M | 37.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.27 B | 6.89 M | 137 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aptorum Group Limited
APM
|
4.09 M | $ 0.79 | -1.15 % | $ 4.31 M |  China |
 |
argenx SE
ARGX
|
13.8 B | $ 700.45 | -1.19 % | $ 25 B |  Niderland |
 |
I-Mab
IMAB
|
127 M | - | - | $ 866 M | China |
 |
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K |  USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
895 M | $ 3.6 | 1.41 % | $ 8.66 B |  Australia |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M |  France |
 |
Grifols, S.A.
GRFS
|
8.42 B | $ 7.81 | -2.01 % | $ 6.83 B |  Spain |
 |
Ascendis Pharma A/S
ASND
|
7.37 B | $ 225.98 | -1.32 % | $ 5 B |  Danmark |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
ADC Therapeutics SA
ADCT
|
1.22 B | $ 4.13 | -5.06 % | $ 105 M |  Schweiz |
 |
AbCellera Biologics
ABCL
|
962 M | $ 3.49 | 0.58 % | $ 1.04 B |  Canada |
 |
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | USA |
 |
BioCardia
BCDA
|
8.9 M | $ 1.26 | -0.79 % | $ 26.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | USA |
 |
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
71.4 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
38.2 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M | Canada |
 |
AlloVir
ALVR
|
49 M | - | 4.14 % | $ 49.1 M | USA |
 |
BioNTech SE
BNTX
|
62.9 B | $ 91.19 | 1.21 % | $ 27.2 B | Germany |
 |
Anika Therapeutics
ANIK
|
373 M | $ 14.2 | -0.7 % | $ 208 M | USA |
 |
Aptinyx
APTX
|
9.48 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Arcturus Therapeutics Holdings
ARCT
|
217 M | $ 6.68 | -4.57 % | $ 183 M |  Israel |
 |
Burford Capital Limited
BUR
|
2.09 B | $ 7.92 | 1.67 % | $ 1.31 B | Britain |
 |
Aytu BioScience
AYTU
|
15.8 M | $ 2.54 | -5.22 % | $ 16 M | USA |
 |
Athersys
ATHX
|
364 M | - | 3.77 % | $ 22.4 M | USA |
 |
Avenue Therapeutics
ATXI
|
544 K | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
424 M | $ 1.44 | -1.37 % | $ 367 M | Britain |
 |
AVEO Pharmaceuticals
AVEO
|
98 M | - | - | $ 521 M | USA |
 |
Athira Pharma
ATHA
|
16.2 M | - | - | $ 269 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.16 B | $ 3.6 | -4.0 % | $ 7.83 B | Israel |
 |
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | Germany |
 |
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | Israel |
 |
Aravive
ARAV
|
60.4 M | - | -13.39 % | $ 1.45 M | USA |
 |
AstraZeneca PLC
AZN
|
81.2 B | - | - | $ 96.9 B | Britain |
 |
Actinium Pharmaceuticals
ATNM
|
48.4 M | $ 1.11 | -1.77 % | $ 33.4 M | USA |